|
Stories from the dialysis comunity across the globe.
|
|
Nuevita´s hospital guarantees Nephrology service to several camagueyan ... - Radio Cadena Agramonte |
 |
 |
- Home
- Articles
- News
- Camagüey
Wednesday, July 8, 2015
 Camaguey, Jul 8.- The service of Nephrology of the teaching general hospital “Martín Chang Puga“, in the coastal municipality of Nuevitas, to the north of this city, attends about 60 patients every day, from this locality and from other municipalities like Sierra de Cubitas , Guáimaro and Minas.
Founded on December 23, 2003, this room has seven artificial kidneys of Fresenius technology and it is the biggest second one of its kind in Camagüey, only preceded by the Center of Nephrology of the university hospital "Manuel Ascunce Domenech", with more than 30 machines of hemodialysis.
Estela Llanes Veiga, chief of this service in "Martín Chang Puga", told AIN that the room has two areas, one for patients without hepatitis and other for bearers of this illness, in order to prevent the transmission of the virus. There is also a water treatment plant.
The annual cost of the dialysis procedures ranges from 30 thousand and 40 thousand euro, according to a multicentric study in Spain published in Internet by the digital magazine Nephrology; nevertheless, in Cuba they are offered completely free.
The chronic renal illness affects 10 % of the world population and its main causes are diabetes mellitus and high blood pressure, therefore, the adoption of healthy life styles can prevent his appearance.
In addition to this service, there are other important specialties in the healthcare facilities such as Gynecology, Surgery, Pediatrics and attention to burned, said Fidel Almaguer Navarro, municipal director of Public Health. (AIN/ Radio Cadena Agramonte)
More from this section ...
|
|
|
Recent research into China's dialysis market trends and forecasts for 2015 ... - WhaTech |
|
|
|
- Advertisement -
In America, the number of the patients who have received the dialysis services from giants-Davita and Fresenius has accounted for 62.7% of the total in 2013, and that of the 9 medium and small chain dialysis institutions has accounted for 15%, nearly 800 non-chain dialysis centers has accounted for 13.6%, and the dialysis centers in hospital has accounted for 8.7%. In general, the average number of patients in each dialysis center is 60-70 people. However, the patients in hospital dialysis centers are no more than 50 people. Obviously, the service ability of independent hemodialysis centers is much greater than those in hospitals.
A typical dialysis center in America is equipped with 18 dialysis machines, and each one of them can give dialysis treatment three times a day, six days a week. Personnel allocation includes five nurses, nine technicians and four supporters (administrative staff, nutritionist and clerk), eighteen members in total. In terms of the distribution of the direct operation cost of American hemodialysis center, manpower cost is a quite important part which covers nearly 40% of the total cost.
Request for Sample:
http://www.marketresearchstore.com/report/research-and-future-development-trend-forecast-of-china-16447#requestSample
Table of Content
1. Overview of Dialysis Industry
1.1 Definition
1.2 Classification
1.3 Development History
2. Global Dialysis Market
2.1 Morbidity of Chronic Renal Failure
2.2 Dialysis Product Market
2.2.1 General Situation of Global Dialysis Product Market
2.2.2 Products Made in Europe, America, and Japan Take up the Lion’s Share in Global Market
2.2.3 Fresenius Becomes the Giant in Manufacturing Hemodialysis Products
2.2.4 Baxter Becomes the Giant in Manufacturing Peritoneal Dialysis Products
2.3 Dialysis Treatment Market
2.3.1 Overview of Global Market
2.3.2 Market Situations in America, Japan, and China
For more information: www.marketresearchstore.com/report/research-and-future-de… < Prev Next >
|
|
Better Hypertension Treatment with Expansion in Insurance Coverage - Renal and Urology News |
|
|
July 08, 2015
Increase expected to lead to fewer coronary heart disease events, stroke events, CVD-related deaths.
(HealthDay News) -- Efforts to expand health insurance coverage are expected to lead to increased treatment rates among nonelderly patients with hypertension, which will have significant health benefits, according to a study published online in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.
Suhui Li, Ph.D., from The George Washington University in Washington D.C., and colleagues developed a state-transition model to simulate lifetime health events of the population aged 25 to 64 years. The effects of insurance coverage expansions were modeled on the basis of published findings on the correlation between insurance coverage, use of antihypertensive medications, and cardiovascular disease (CVD)-related events and deaths.
The researchers found that among patients with hypertension, currently anticipated health insurance expansions would lead to a 5.1% increase in treatment rates. By 2050, this increase would be expected to lead to 111,000 fewer new coronary heart disease events, 63,000 fewer stroke events, and 95,000 fewer CVD-related deaths. Slightly greater estimated benefits were seen for men than women, and for nonwhite populations.
"Federal and state efforts to expand insurance coverage among nonelderly adults could yield significant health benefits in terms of CVD prevalence and mortality rates and narrow the racial/ethnic disparities in health outcomes for patients with hypertension," the authors write.
Source
- Li S, Bruen BK, Lantz PM, Mendez D. Impact of Health Insurance Expansions on Nonelderly Adults With Hypertension. Prev Chronic Dis2015;12:150111; doi: 10.5888/pcd12.150111.
|
|
|
Zacks Rating on Fresenius Medical Care Corporation - News Watch International |
|
|
|
Fresenius Medical Care Corporation (NYSE:FMS) is a hold, according to the latest average broker rating of 2.63. The number of analysts in this rating is 8. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation is Neutral on the company.
Fresenius Medical Care Corporation (NYSE:FMS) should head towards $43.91 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $39 per share. The higher price estimate target is at $50 according to the Analysts. Institutional Investors own 2% of Company shares. During last 3 month period, 0.23% of total institutional ownership has changed in the company shares.
Shares of Fresenius Medical Care Corporation (NYSE:FMS) ended Monday session in red amid volatile trading. The shares closed down 0.74 points or 1.79% at $40.62 with 318,120 shares getting traded. Post opening the session at $40.47, the shares hit an intraday low of $40.43 and an intraday high of $40.9 and the price vacillated in this range throughout the day. The company has a market cap of $25,359 million and the number of outstanding shares has been calculated to be 624,304,000 shares. The 52-week high of Fresenius Medical Care Corporation (NYSE:FMS) is $44.34 and the 52-week low is $32.4. The company shares have rallied 21.47% from its 1 Year high price. On Jun 4, 2015, the shares registered one year high at $44.34 and the one year low was seen on Oct 16, 2014. The 50-Day Moving Average price is $42.81 and the 200 Day Moving Average price is recorded at $40.41. Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patients peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers.
NO COMMENTS
LEAVE A REPLY
|
|
Renault helps dialysis patients support - Irish Car+Travel (blog) |
|
|
|
Renault Ireland has presented a Renault Captur 1.5 dCi Intense to Rathfarnham man Michael Mangan of Patient 2 Patient Shared Experiences which is a non-profit, patient-focused organisation that provides non-medical advice to those affected by chronic kidney disease, writes Trish Whelan.
The free support service offers patients the opportunity to discuss their condition, feelings and treatment with fellow patients who have already been through the experience.
Patient Support Co-ordinator Michael says that the new Renault Captur is a huge asset in allowing him to meet up with patients who are on dialysis and awaiting kidney transplants.
“I use the experiences of my illness along with other patients who have had successful transplants to help new patients deal with the many challenges that lie ahead for them.”
The married father of three from Rathfarnham has had two kidney transplants over a 20 year period and he now needs a third kidney.
Pictured above at the handover of the Renault Captur at Renault Belgard are David Hickey, the Director of the National Kidney & Pancreas Transplant Program, who has performed over 1500 transplants; Michael Mangan; and Lynne Boucher, Marketing Manager, Renault Group Ireland.
HOME PAGE
|
|
|
|
|
<< Start < Prev 111 112 113 114 115 116 117 118 119 120 Next > End >>
|
|
Page 112 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
